Cytoreduction for ET and PV: who, what, when, and how?

2.

Verstovsek

S

,

Pemmaraju

N

,

Reaven

NL

, et al.

Real-world treatments and thrombotic events in polycythemia vera patients in the USA

.

Ann Hematol

.

2023

;

102

(

3

):

571

-

581

.

doi:10.1007/s00277-023-05089-6

.

3.

Pemmaraju

N

,

Gerds

AT

,

Yu

J

, et al.

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia

.

Leuk Res

.

2022

;

115

(April):

106809

.

doi:10.1016/j.leukres.2022.106809

.

4.

Gerds

AT

,

Gotlib

J

,

Ali

H

, et al.

Myeloproliferative Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

. Vols.

2-23

.

Plymouth Meeting, PA

:

National Comprehensive Cancer Network

;

2023

. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed

April

7

,

2023

.

5.

Barbui

T

,

Tefferi

A

,

Vannucchi

AM

, et al.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

.

Leukemia

.

2018

;

32

(

5

):

1057

-

1069

.

doi:10.1038/s41375-018-0077-1

.

6.

Marchetti

M

,

Vannucchi

AM

,

Griesshammer

M

, et al.

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

.

Lancet Haematol

.

2022

;

9

(

4

):

e301

-

e311

.

doi:10.1016/S2352-3026(22)00046-1

.

7.

Mesa

RA

,

Jamieson

C

,

Bhatia

R

, et al.

NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018

.

J Natl Compr Canc Netw

.

2017

;

15

(

10

):

1193

-

1207

.

doi:10.6004/jnccn.2017.0157

.

8.

NCCN Guidelines Version 2.2021

.

Myeloproliferative Neoplasms

.

Plymouth Meeting, PA

:

National Comprehensive Cancer Network

;

2021

.

9.

Marchioli

R

,

Finazzi

G

,

Landolfi

R

, et al.

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

.

J Clin Oncol

.

2005

;

23

(

10

):

2224

-

2232

.

doi:10.1200/JCO.2005.07.062

.

10.

Barbui

T

,

Finazzi

G

,

Carobbio

A

, et al.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-Essential Thrombocythemia (IPSET-thrombosis)

.

Blood

.

2012

;

120

(

26

):

5128

-

5133

; quiz 5252. doi:10.1182/blood-2012-07-444067

.

11.

Hultcrantz

M

,

Björkholm

M

,

Dickman

PW

, et al.

Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study

.

Ann Intern Med

.

2018

;

168

(

5

):

317

-

325

.

doi:10.7326/M17-0028

.

12.

Besses

C

,

Cervantes

F

,

Pereira

A

, et al.

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

.

Leukemia

.

1999

;

13

(

2

):

150

-

154

.

doi:10.1038/sj.leu.2401270

.

13.

Tefferi

A

,

Wassie

EA

,

Guglielmelli

P

, et al.

Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

.

Am J Hematol

.

2014

;

89

(

8

):

E121

-

E124

.

doi:10.1002/ajh.23743

.

14.

Rumi

E

,

Pietra

D

,

Ferretti

V

, et al;

Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

.

Blood

.

2014

;

123

(

10

):

1544

-

1551

.

doi:10.1182/blood-2013-11-539098

.

15.

Passamonti

F

,

Thiele

J

,

Girodon

F

, et al.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

.

Blood

.

2012

;

120

(

6

):

1197

-

1201

.

doi:10.1182/blood-2012-01-403279

.

16.

Tefferi

A

,

Rumi

E

,

Finazzi

G

, et al.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

.

Leukemia

.

2013

;

27

(

9

):

1874

-

1881

.

doi:10.1038/leu.2013.163

.

17.

Tefferi

A

,

Guglielmelli

P

,

Lasho

TL

, et al.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

.

Br J Haematol

.

2020

;

189

(

2

):

291

-

302

.

doi:10.1111/bjh.16380

.

18.

Harrison

CN

,

Koschmieder

S

,

Foltz

L

, et al.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey

.

Ann Hematol

.

2017

;

96

(

10

):

1653

-

1665

.

doi:10.1007/s00277-017-3082-y

.

19.

Pratt

JJ

,

Khan

KS

.

Non-anaemic iron deficiency—a disease looking for recognition of diagnosis: a systematic review

.

Eur J Haematol

.

2016

;

96

(

6

):

618

-

628

.

doi:10.1111/ejh.12645

.

20.

Ronner

L

,

Podoltsev

N

,

Gotlib

J

, et al.

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

.

Blood

.

2020

;

135

(

19

):

1696

-

1703

.

doi:10.1182/blood.2019003347

.

21.

Coltoff

A.

Leukocytosis and MPNs: where do we stand?

Leuk Lymphoma

.

2023

;

64

(

3

):

564

-

572

.

doi:10.1080/10428194.2022.2156794

.

22.

Carobbio

A

,

Ferrari

A

,

Masciulli

A

,

Ghirardi

A

,

Barosi

G

,

Barbui

T.

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

.

Blood Adv

.

2019

;

3

(

11

):

1729

-

1737

.

doi:10.1182/bloodadvances.2019000211

.

23.

Mesa

R

,

Miller

CB

,

Thyne

M

, et al.

Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey

.

BMC Cancer

.

2016

;

16

(

February

):

167

.

doi:10.1186/s12885-016-2208-2

.

24.

Andriani

A

,

Latagliata

R

,

Anaclerico

B

, et al.

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients

.

Am J Hematol

.

2016

;

91

(

3

):

318

-

321

.

doi:10.1002/ajh.24269

.

25.

Vannucchi

AM

,

Kiladjian

JJ

,

Griesshammer

M

, et al.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

.

N Engl J Med

.

2015

;

372

(

5

):

426

-

435

.

doi:10.1056/NEJMoa1409002

.

26.

Barbui

T

,

Vannucchi

AM

,

De Stefano

V

, et al.

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

.

Lancet Haematol

.

2021

;

8

(

3

):

e175

-

e184

.

doi:10.1016/S2352-3026(20)30373-2

.

27.

Mazza

GL

,

Mead-Harvey

C

,

Mascarenhas

J

, et al.

Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

.

Lancet Haematol

.

2022

;

9

(

1

):

e38

-

e48

.

doi:10.1016/S2352-3026(21)00343-4

.

28.

Cortelazzo

S

,

Finazzi

G

,

Ruggeri

M

, et al.

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

.

N Engl J Med

.

1995

;

332

(

17

):

1132

-

1136

.

doi:10.1056/NEJM199504273321704

.

29.

Godfrey

AL

,

Campbell

PJ

,

MacLean

C

, et al;

United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; Australasian Leukaemia and Lymphoma Group

.

Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features

.

J Clin Oncol

.

2018

;

36

(

34

):

3361

-

3369

.

doi:10.1200/JCO.2018.78.8414

.

30.

Yacoub

A

,

Mascarenhas

J

,

Kosiorek

H

, et al.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

.

Blood

.

2019

;

134

(

18

):

1498

-

1509

.

doi:10.1182/blood.2019000428

.

31.

Mascarenhas

J

,

Kosiorek

HE

,

Prchal

JT

, et al.

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

.

Blood

.

2022

;

139

(

19

):

2931

-

2941

.

doi:10.1182/blood.2021012743

.

. https://library.ehaweb.org/eha/2019/24th/267363/trine.alma.knudsen.three-year.analysis.of.the.daliah.trial.-.a.randomized.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1

32.

Knudsen

T

,

Hansen

D

,

Ocias

L

, et al.

Three-year analysis of the Daliah trial—a randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms

. Paper presented at: European Hematology Association Annual Meeting: Amsterdam;

2019

33.

Knudsen

TA

,

Skov

V

,

Stevenson

K

, et al.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

.

Blood Adv

.

2022

;

6

(

7

):

2107

-

2119

.

doi:10.1182/bloodadvances.2021004856

.

34.

Tomer

A.

Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia

.

Blood

.

2002

;

99

(

5

):

1602

-

1609

.

doi:10.1182/blood.v99.5.1602

.

35.

Harrison

CN

,

Campbell

PJ

,

Buck

G

, et al.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

.

N Engl J Med

.

2005

;

353

(

1

):

33

-

45

.

doi:10.1056/nejmoa043800

.

36.

Gisslinger

H

,

Gotic

M

,

Holowiecki

J

, et al;

ANAHYDRET Study Group

.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial

.

Blood

.

2013

;

121

(

10

):

1720

-

1728

.

doi:10.1182/blood-2012-07-443770

.

37.

Anagrelide Study Group

.

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients

.

Am J Med

.

1992

;

92

(

1

):

69

-

76

.

doi:10.1016/0002-9343(92)90017-6

.

38.

Barbui

T

,

Vannucchi

AM

,

Finazzi

G

, et al.

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study

.

Am J Hematol

.

2017

;

92

(

11

):

1131

-

1136

.

doi:10.13039/501100005010

.

39.

Passamonti

F

,

Griesshammer

M

,

Palandri

F

, et al.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

.

Lancet Oncol

.

2017

;

18

(

1

):

88

-

99

.

doi:10.1016/s1470-2045(16)30558-7

.

40.

Harrison

CN

,

Nangalia

J

,

Boucher

R

, et al.

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

.

J Clin Oncol

.

2023

;

41

(

19

):

3534

-

3544

.

doi:10.1200/jco.22.01935

.

41.

Masciulli

A

,

Ferrari

A

,

Carobbio

A

,

Ghirardi

A

,

Barbui

T.

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis

.

Blood Adv

.

2020

;

4

(

2

):

380

-

386

.

doi:10.1182/bloodadvances.2019001158

.

42.

Alvarez-Larrán

A

,

Martínez-Avilés

L

,

Hernández-Boluda

JC

, et al.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

.

Ann Hematol

.

2014

;

93

(

12

):

2037

-

2043

.

doi:10.1007/s00277-014-2152-7

.

43.

Finazzi

G

,

Caruso

V

,

Marchioli

R

, et al;

ECLAP Investigators

.

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

.

Blood

.

2005

;

105

(

7

):

2664

-

2670

.

doi:10.1182/blood-2004-09-3426

.

44.

Knudsen

TA

,

Hansen

DL

,

Ocias

LF

, et al.

Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the Daliah trial—a randomized controlled phase III clinical trial

.

Blood

.

2018

;

132

(

November

):

580

.

doi:10.1182/blood-2018-99-111255

.

45.

Gisslinger

H

,

Klade

C

,

Georgiev

P

, et al;

PROUD-PV Study Group

.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

.

Lancet Haematol

.

2020

;

7

(

3

):

e196

-

e208

.

doi:10.1016/S2352-3026(19)30236-4

.

46.

Abu-Zeinah

G

,

Krichevsky

S

,

Cruz

T

, et al.

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival

.

Leukemia

.

2021

;

35

(

9

):

2592

-

2601

.

doi:10.1038/s41375-021-01183-8

.

47.

Barosi

G

,

Mesa

R

,

Finazzi

G

, et al.

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

.

Blood

.

2013

;

121

(

23

):

4778

-

4781

.

doi:10.1182/blood-2013-01-478891

.

48.

Hernández-Boluda

JC

,

Alvarez-Larrán

A

,

Gómez

M

, et al.

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia: hydroxycarbamide in essential thrombocythaemia

.

Br J Haematol

.

2011

;

152

(

1

):

81

-

88

.

doi:10.1111/j.1365-2141.2010.08430.x

.

49.

Hernández-Boluda

JC

,

Pereira

A

,

Cervantes

F

, et al.

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

.

Ann Hematol

.

2013

;

92

(

6

):

771

-

775

.

doi:10.1007/s00277-013-1683-7

.

50.

Alvarez-Larrán

A

,

Pereira

A

,

Cervantes

F

, et al.

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

.

Blood

.

2012

;

119

(

6

):

1363

-

1369

.

doi:10.1182/blood-2011-10-387787

.

51.

Tremblay

D

,

Srisuwananukorn

A

,

Ronner

L

, et al.

European LeukemiaNet response predicts disease progression but not thrombosis in polycythemia vera

.

HemaSphere

.

2022

;

6

(

6

):

e721

.

doi:10.1097/hs9.0000000000000721

.

52.

Campbell

PJ

,

MacLean

C

,

Beer

PA

, et al.

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

.

Blood

.

2012

;

120

(

7

):

1409

-

1411

.

doi:10.1182/blood-2012-04-424911

.

53.

Kuykendall

AT

,

Komrokji

R.

What's in a number? Examining the prognostic and predictive importance of platelet count in patients with essential thrombocythemia

.

J Natl Compr Canc Netw

.

2020

;

18

(

9

):

1279

-

1284

.

doi:10.6004/jnccn.2020.7595

.

54.

Alvarez-Larrán

A

,

Pérez-Encinas

M

,

Ferrer-Marín

F

, et al;

Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas

.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

.

Haematologica

.

2017

;

102

(

1

):

103

-

109

.

doi:10.3324/haematol.2016.152769

.

55.

Beauverd

Y

,

Radia

D

,

Cargo

C

, et al.

Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series

.

Haematologica

.

2016

;

101

(

5

):

e182

-

e184

.

doi:10.3324/haematol.2015.139691

.

56.

Griesshammer

M

,

Andreoli

A

,

Schauer

S

, et al.

Outcomes of 121 pregnancies in patients with polycythemia vera (PV). Haematologica

.

Pavia, Italy

:

Ferrata Storti Foundation

;

2016

.

57.

Wang

R

,

Shallis

RM

,

Stempel

JM

, et al.

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

.

Blood Adv

.

2023

;

7

(

5

):

734

-

743

.

doi:10.1182/bloodadvances.2022008259

.

58.

Hasselbalch

HC

.

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

.

Expert Rev Hematol

.

2011

;

4

(

6

):

637

-

655

.

doi:10.1586/ehm.11.63

.